Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 561-579

  Sandgren, Johanna ^a,b   Diaz De Stahl, Teresita ^b   Andersson, Robin ^c   Menzel, Uwe ^b   Piotrowski, Arkadiusz ^d   Nord, Helena ^b   Bäckdahl, Martin ^e   Kiss, Nimrod B ^e   Brauckhoff, Michael ^f   Komorowski, Jan ^c   Dralle, Henning ^f   Hessman, Ola ^a   Larsson, Catharina ^e   Åkerström, Göran ^a   Bruder, Carl ^g   Dumanski, Jan P ^b   Westin, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ADRENAL TUMOR; ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER RECURRENCE; CATECHOLAMINE RELEASE; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 3Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOCRINE TUMOR; FEMALE; GENE MUTATION; GENOME; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; ADOLESCENT; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAGANGLIOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955811444     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0310     Document Type: Article

References (82)

1. Aarts M, Dannenberg H, deLeeuw RJ, van Nederveen FH, Verhofstad AA, Lenders JW, Dinjens WN, Speel EJ, Lam WL & de Krijger RR 2006 Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes, Chromosomes & Cancer 45 83-93. (Pubitemid 46930864)
2. Albertson DG 2006 Gene amplification in cancer. Trends in Genetics 22 447-455.
3. Ameur A, Yankovski V, Enroth S, Spjuth O & Komorowski J 2006 The LCB Data Warehouse. Bioinformatics 22 1024-1026.
4. Andersson R, Bruder CE, Piotrowski A, Menzel U, Nord H, Sandgren J, Hvidsten TR, Diaz de Stahl T, Dumanski JP & Komorowski J 2008 A segmental maximum a posteriori approach to genome-wide copy number profiling. Bioinformatics 24 751-758. (Pubitemid 351386912)
5. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F & Maher ER 2001a Germline SDHD mutation in familial phaeochromocytoma. Lancet 357 1181-1182. (Pubitemid 32378695)
6. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C & Maher ER 2001b Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics 69 49-54. (Pubitemid 32614017)
7. August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, Kersting C & Buerger H 2004 CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Modern Pathology 17 1119-1128. (Pubitemid 39128238)
8. Bagchi A & Mills AA 2008 The quest for the 1p36 tumor suppressor. Cancer Research 68 2551-2556.
9. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN et al. 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 848-851.
10. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C & Neumann HP 2000 Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 85 4568-4574. (Pubitemid 32157635)
11. Borkosky SS, Gunduz M, Nagatsuka H, Beder LB, Gunduz E, Ali MA, Rodriguez AP, Cilek MZ, Tominaga S, Yamanaka N et al. 2009 Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology 135 703-713.
12. Bravo EL & Tagle R 2003 Pheochromocytoma: state-of-the-art and future prospects. Endocrine Reviews 24 539-553.
13. Bryant J, Farmer J, Kessler LJ, Townsend RR & Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 1196-1204. (Pubitemid 37069549)
14. Buckley PG, Mantripragada KK, Benetkiewicz M, Tapia-Paez I, Diaz De Stahl T, Rosenquist M, Ali H, Jarbo C, De Bustos C, Hirvela C et al. 2002 A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Human Molecular Genetics 11 3221-3229.
15. Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W & Zhang Y 2009 Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochemical and Biophysical Research Communications 380 11-16.
16. Cascon A, Ruiz-Llorente S, Rodriguez-Perales S, Honrado E, Martinez-Ramirez A, Leton R, Montero-Conde C, Benitez J, Dopazo J, Cigudosa JC et al. 2005 A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. Genes, Chromosomes & Cancer 42 260-268.
17. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P & Wood CG 2003 Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22 8053-8062. (Pubitemid 37175870)
18. Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Abdelmohsen K, Gorospe M & Kern SE 2006a Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers. Cell Cycle 5 1090-1093. (Pubitemid 43765305)
19. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue C, Ashfaq R, Kern SE, Maitra A, Heitmiller RE et al. 2006b MKK4 status predicts survival after resection of gastric adenocarcinoma. Archives of Surgery 141 1095-1099.
20. Dannenberg H, Speel EJ, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi WJ et al. 2000 Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. American Journal of Pathology 157 353-359. (Pubitemid 30626902)
21. Dannenberg H, Komminoth P, Dinjens WN, Speel EJ & de Krijger RR 2003 Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocrine Pathology 14 329-350. (Pubitemid 38903386)
22. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R & Resar LM 2008 HMGA2 participates in transformation in human lung cancer. Molecular Cancer Research 6 743-750.
23. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR & Blobe GC 2007 The type III TGF-beta receptor suppresses breast cancer progression. Journal of Clinical Investigation 117 206-217. (Pubitemid 46048467)
24. Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Teh BT, Backdahl M & Larsson C 2000 Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. American Journal of Pathology 156 651-659. (Pubitemid 30643820)
25. Edstrom Elder E, Hjelm Skog AL, Hoog A & Hamberger B 2003 The management of benign and malignant pheochromocytoma and abdominal paraganglioma. European Journal of Surgical Oncology 29 278-283. (Pubitemid 36395565)
26. Elder EE, Elder G & Larsson C 2005 Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Journal of Surgical Oncology 89 193-201. (Pubitemid 40315916)
27. Eng C, Kiuru M, Fernandez MJ & Aaltonen LA 2003 A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Reviews. Cancer 3 193-202. (Pubitemid 37328871)
28. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA & Young WF Jr 2001 Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. Journal of Clinical Endocrinology and Metabolism 86 5210-5216. (Pubitemid 33070237)
29. Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G & Jenuwein T 2006 Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes and Development 20 1557-1562. (Pubitemid 43901094)
30. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB et al. 2008 CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute 100 940-949.
31. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG et al. 2009 SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325 1139-1142.
32. Heidenblad M, Lindgren D, Jonson T, Liedberg F, Veerla S, Chebil G, Gudjonsson S, Borg A, Mansson W & Hoglund M 2008 Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Medical Genomics 1 3.
33. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D, Burchard J, Dow S, Ward TR, Kidd MJ et al. 2000 Widespread aneuploidy revealed by DNA microarray expression profiling. Nature Genetics 25 333-337. (Pubitemid 30437324)
34. Jarbo C, Buckley PG, Piotrowski A, Mantripragada KK, Benetkiewicz M, de Stahl TD, Langford CF, Gregory SG, Dralle H, Gimm O et al. 2006 Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. International Journal Cancer 118 1159-1164.
35. Johnstone CN, Castellvi-Bel S, Chang LM, Sung RK, Bowser MJ, Pique JM, Castells A & Rustgi AK 2005 PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas. Genomics 85 338-351. (Pubitemid 40249426)
36. Kallioniemi A 2008 CGH microarrays and cancer. Current Opinion in Biotechnology 19 36-40.
37. Karagiannis A, Mikhailidis DP, Athyros VG & Harsoulis F 2007 Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer 14 935-956.
38. Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H, Gotoh T, Motoi T, Fukayama M, Aburatani H et al. 2006 Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Human Molecular Genetics 15 2125-2137.
39. Kiss NB, Geli J, Lundberg F, Avci C, Velazquez-Fernandez D, Hashemi J, Weber G, Hoog A, Ekstrom TJ, Backdahl M et al. 2008 Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Endocrine-Related Cancer 15 609-621. (Pubitemid 351880847)
40. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P et al. 2008 Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clinical Cancer Research 14 5357-5367.
41. Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM & Wang F 2008 Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. International Journal of Cancer 123 543-551. (Pubitemid 351898411)
42. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 1317-1320. (Pubitemid 23231974)
43. Lee CJ, Chan WI & Scotting PJ 2005 CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. Journal of Neuro-Oncology 73 101-108.
44. Li J, Wang F, Haraldson K, Protopopov A, Duh FM, Geil L, Kuzmin I, Minna JD, Stanbridge E, Braga E et al. 2004 Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Research 64 6438-6443.
45. Linnoila RI, Keiser HR, Steinberg SM & Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology 21 1168-1180.
46. Mailand N, Lukas C, Kaiser BK, Jackson PK, Bartek J & Lukas J 2002 Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. Nature Cell Biology 4 317-322. (Pubitemid 34308859)
47. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460. (Pubitemid 23179393)
48. van Nederveen F, Korpershoek E, deLeeuw R, Verhofstad AA, Lenders JW, Dinjens WNM, Lam WL & de Krijger RR 2009 Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocrine-Related Cancer 16 505-513.
49. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al. 2002 Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466.
50. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA et al. 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Journal of the American Medical Association 292 943-951.
51. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A et al. 2005 The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8 355-368.
52. Niemann S & Muller U 2000 Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 26 268-270.
53. Pasini B & Stratakis CA 2009 SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. Journal of Internal Medicine 266 19-42.
54. Paulsen MT, Starks AM, Derheimer FA, Hanasoge S, Li L, Dixon JE & Ljungman M 2006 The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers. Molecular Cancer 5 25. (Pubitemid 44144863)
55. Persson F, Andren Y, Winnes M, Wedell B, Nordkvist A, Gudnadottir G, Dahlenfors R, Sjogren H, Mark J & Stenman G 2009 High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes, Chromosomes & Cancer 48 69-82.
56. Petri BJ, Speel EJ, Korpershoek E, Claessen SM, van Nederveen FH, Giesen V, Dannenberg H, van der Harst E, Dinjens WN & de Krijger RR 2008 Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Modern Pathology 21 407-413. (Pubitemid 351441028)
57. Piotrowski A, Bruder CE, Andersson R, de Stahl TD, Menzel U, Sandgren J, Poplawski A, von Tell D, Crasto C, Bogdan A et al. 2008 Somatic mosaicism for copy number variation in differentiated human tissues. Human Mutation 29 1118-1124.
58. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL & Brown PO 2002 Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. PNAS 99 12963-12968.
59. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L et al. 2008 Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clinical Cancer Research 14 41-47. (Pubitemid 351377976)
60. Ricketts SL, Carter JC & Coleman WB 2003 Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genes. Molecular Carcinogenesis 36 90-99.
61. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS et al. 2008 The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics 1 13.
62. Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M et al. 2007 Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 28 2459-2466.
63. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK & Gershenson DM 2006 The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biology & Therapy 5 1136-1141. (Pubitemid 44772228)
64. Sharifi N, Lechleider RJ & Farrar WL 2007 Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate? Journal of Molecular Endocrinology 39 329-332.
65. Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML, Settleman J & Chen RH 2008 Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Research 68 7779-7787.
66. Shi ZZ, Zhang JW & Zheng S 2007 What we know about ST13, a co-factor of heat shock protein, or a tumor suppressor? Journal of Zhejiang University. Science. B 8 170-176.
67. de Stahl TD, Sandgren J, Piotrowski A, Nord H, Andersson R, Menzel U, Bogdan A, Thuresson AC, Poplawski A, von Tell D et al. 2008 Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. Human Mutation 29 398-408.
68. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M & Ghossein RA 2008 Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143 759-768.
69. Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, Lee JM, Gray JW & Auersperg N 2008 The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. International Journal of Cancer 123 1761-1769.
70. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T & Saji S 2000 Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 47 268-271. (Pubitemid 30489772)
71. Thompson LD 2002 Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. American Journal of Surgical Pathology 26 551-566.
72. Tischler AS 2008 Pheochromocytoma and extra-adrenal paraganglioma: updates. Archives of Pathology & Laboratory Medicine 132 1272-1284.
73. Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE et al. 2008 High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clinical Cancer Research 14 2527-2534.
74. Wang XC, Tian J, Tian LL, Wu HL, Meng AM, Ma TH, Xiao J, Xiao XL & Li CH 2009 Role of Cks1 amplification and overexpression in breast cancer. Biochemical and Biophysical Research Communications 379 1107-1113.
75. Weber F & Eng C 2008 Update on the molecular diagnosis of endocrine tumors: toward -omics-based personalized healthcare? Journal of Clinical Endocrinology and Metabolism 93 1097-1104.
76. Wiencke JK, Zheng S, Morrison Z & Yeh RF 2008 Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27 2412-2421. (Pubitemid 351521100)
77. Xu W, Mulligan LM, Ponder MA, Liu L, Smith BA, Mathew CG & Ponder BA 1992 Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes, Chromosomes & Cancer 4 337-342.
78. Yang M, Cao X, Yu MC, Gu JF, Shen ZH, Ding M, Yu de B, Zheng S & Liu X 2008 Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death. Human Gene Therapy 19 343-353. (Pubitemid 351591426)
79. Ythier D, Larrieu D, Brambilla C, Brambilla E & Pedeux R 2008 The new tumor suppressor genes ING: genomic structure and status in cancer. International Journal of Cancer 123 1483-1490.
80. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B & Shaughnessy JD Jr 2007 CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109 4995-5001. (Pubitemid 46827799)
81. Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS & Xia JC 2008 Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Letters 261 183-192.
82. Zhu H, Lam DC, Han KC, Tin VP, Suen WS, Wang E, Lam WK, Cai WW, Chung LP & Wong MP 2007 High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Letters 245 303-314. (Pubitemid 44959355)